微信公众号

官网二维码

中国癌症防治杂志 ›› 2024, Vol. 16 ›› Issue (5): 566-570.doi: 10.3969/j.issn.1674-5671.2024.05.09

• CAR-T细胞治疗专栏 • 上一篇    下一篇

新型冠状病毒感染与CAR-T耐药双重挑战下的格菲妥单抗治疗:难治性弥漫大B细胞淋巴瘤1例报告

  

  1. 中国医学科学院北京协和医院内科学系;中国医学科学院北京协和医院血液内科
  • 出版日期:2024-10-25 发布日期:2024-11-06
  • 通讯作者: 王为 E-mail: wangweipumc@163.com
  • 基金资助:
    北京协和医学院2023年中央高校教育教学改革专项资金支持项目(2023zlgl 050)

Glofitamab therapy under the dual challenge of novel coronavirus infection and CAR-T resistance: a case report of refractory diffuse large B-cell lymphoma

  • Online:2024-10-25 Published:2024-11-06

摘要: 本文总结1例嵌合抗原受体T(chimeric antigen receptor T,CAR⁃T)细胞治疗失败的难治性弥漫大B细胞淋巴瘤患者,在合并新型冠状病毒(coronavirus disease 2019,COVID⁃19)情况下接受格菲妥单抗治疗后获得完全缓解,且未见COVID⁃19感染加重等其他严重不良反应的治疗经验,同时回顾文献中格菲妥单抗治疗难治性弥漫大B细胞淋巴瘤的疗效,以及双特异性抗体在合并COVID⁃19的淋巴瘤患者中的安全性。

关键词: 弥漫性大B细胞淋巴瘤, 嵌合抗原受体T细胞, 格菲妥单抗, 双特异性抗体, 新型冠状病毒, 淋巴瘤

Abstract: The data of a patient with refractory diffuse large B⁃cell lymphoma, who was failed to chimeric antigen receptor T (CAR⁃T) cell therapy, are analyzed in this report. The patient achieved complete remission after receiving glofitamab with combination of coronavirus disease 2019 (COVID⁃19), and no other serious adverse events such as aggravation of COVID⁃19 were observed. Meanwhile, the efficacy of Glofitamab in the treatment of refractory diffuse large B⁃cell lymphoma is reviewed, and the safety of bispecific antibodies in patients with lymphoma complicated with COVID⁃19 is evaluated.

Key words: Diffuse large B cell lymphoma, Chimeric antigen receptor T cell, Glofitamab, Bispecific antibody, COVID?19, Lymphoma

中图分类号: 

  • R733.4